PGT-A in 2026: Is Preimplantation Genetic Testing Worth It?

If you have spent any time on r/IVF, you have seen the question: "Should I add PGT-A to my cycle?" It is one of the most-asked, most-debated, and most-expensive add-on decisions in IVF today. The honest answer is: it depends on your age, your diagnosis, and how many embryos you are likely to make.

This guide walks through what PGT-A actually tests, what the best available evidence says, who it most likely helps, and the cases where the cost may not be justified.

What PGT-A actually is (and what it is not)

PGT-A stands for Preimplantation Genetic Testing for Aneuploidy. After your eggs are retrieved and fertilized, embryos are grown in the lab to the blastocyst stage (typically day 5, 6, or 7). A handful of cells (usually 5-10) are biopsied from the trophectoderm — the outer layer that will become the placenta, not the fetus itself. Those cells are sent to a reference genetics lab, where next-generation sequencing counts the chromosomes.

The goal is to identify euploid embryos (the correct 46 chromosomes) and avoid transferring aneuploid embryos (extra or missing chromosomes), which are the leading cause of failed implantation and first-trimester miscarriage.

PGT-A is often confused with two related but very different tests:

• PGT-M (Monogenic): Tests for a specific single-gene disorder when you and your partner are known carriers (e.g., cystic fibrosis, Huntington's, BRCA1/2 in some cases).
• PGT-SR (Structural Rearrangements): Tests for unbalanced embryos when one partner carries a known balanced translocation or inversion.

PGT-M and PGT-SR are usually clearly indicated and rarely controversial. PGT-A is the one with the mixed evidence and the loud debate.

The cost: $3,000-$6,000 added per cycle

PGT-A is almost never bundled into a base IVF price. In Canada and the US in 2026, typical pricing breaks down as:

• Biopsy fee (the embryologist taking the cells): $1,000-$2,000
• Per-embryo lab fee (the genetics analysis): $300-$500 per embryo, often capped at 6-8 embryos
• Shipping and handling to the reference lab: $150-$400

If you have 6 embryos to biopsy, you are realistically looking at $3,500-$6,000 on top of your base cycle cost. Some clinics offer flat-rate packages; others charge per embryo with no cap.

The evidence: the STAR trial changed the conversation

In 2019, Munné and colleagues published the STAR trial in Fertility and Sterility — a multi-center randomized controlled trial that is still the most-cited piece of evidence in the PGT-A debate. The key finding: in women aged 25 to 40 with a good prognosis (at least two blastocysts available), PGT-A did not improve the per-transfer live birth rate compared to morphology-based embryo selection.

For women under 35, ongoing pregnancy rates were essentially identical (about 50% vs 46%). The trial concluded that for younger patients with multiple good-quality blastocysts, PGT-A's main benefit was a slightly faster time-to-pregnancy and fewer miscarriages — not more babies overall.

The ASRM Practice Committee has since issued opinions stating that the value of PGT-A for general IVF use remains unproven, and that it should be offered selectively. The UK's HFEA rates PGT-A as amber (yellow) on its Traffic Light System, meaning the evidence is mixed and patients should be counseled carefully before paying for it.

SART (Society for Assisted Reproductive Technology) data shows that while euploid embryo transfers do have higher per-transfer success rates across age bands, cumulative live birth rates per egg retrieval are often similar whether or not PGT-A is used — because some of the embryos discarded as "abnormal" might have self-corrected or were misdiagnosed.

The mosaicism problem

This is the part that has shifted the conversation in the last few years. PGT-A biopsies sometimes come back as mosaic — meaning some of the biopsied cells were euploid and some were aneuploid. Historically, mosaic embryos were discarded.

Multiple follow-up studies (including work from the International Registry of Mosaic Embryo Transfers) have shown that many mosaic embryos result in healthy, chromosomally normal live births. The biopsy of 5-10 cells from the trophectoderm is also an imperfect snapshot — there is a real false-positive rate, especially for segmental aneuploidies.

The practical concern: a patient with limited embryos who discards a "low-level mosaic" on the advice of an older lab protocol may have thrown away their best chance at a healthy baby.

When PGT-A is most likely worth it

Based on current evidence, PGT-A has the strongest case in these scenarios:

1. Advanced maternal age (38+): Aneuploidy rates rise sharply with egg age — from roughly 30% at age 35 to over 70% at age 42. Identifying euploid embryos can reduce time-to-pregnancy and lower miscarriage risk.
2. Recurrent pregnancy loss (2+ losses, especially if karyotyping showed chromosomal causes)
3. Recurrent implantation failure (3+ failed transfers of good-quality embryos)
4. Known balanced translocation in either partner (technically PGT-SR territory, but often paired with PGT-A)
5. Single embryo transfer is mandated by your clinic or your medical situation, and you want the highest per-transfer odds

See our Add-On Evidence Traffic Light for evidence ratings on PGT-A, ICSI, ERA, EmbryoGlue, and the other add-ons your clinic may offer.

When PGT-A may not be worth it

• First IVF cycle, patient under 35, normal ovarian reserve, no recurrent loss: The STAR trial directly addressed this group. The evidence does not support routine PGT-A here.
• Very low embryo numbers (1-2 blastocysts): Biopsy carries a small risk of damaging the embryo (estimated 1-2%). With only one or two embryos, the cost-benefit shifts toward transferring untested.
• Patients on a tight budget where the $3K-$6K would be better spent on a second egg retrieval to bank more embryos.
• Patients who would transfer a mosaic embryo anyway — in which case the test result may not change your decision.

Questions to ask your clinic before saying yes

• What is your clinic's biopsy damage rate?
• Which reference lab do you use, and what is their no-result/inconclusive rate?
• How do you counsel mosaic results — discard, transfer with consent, or case-by-case?
• What is your euploid transfer success rate by maternal age band?
• Will you cap the per-embryo fee, or do I pay for every blastocyst?

The answers matter. A clinic that automatically discards all mosaics and another that offers genetic counseling and considered transfer will produce very different outcomes for the same patient.

The bottom line for 2026

PGT-A is not a scam, and it is not a magic bullet. It is a selective tool that helps specific patient groups — primarily older patients, those with recurrent loss, and those with structural rearrangements. For a healthy 32-year-old on her first cycle with eight good blastocysts, the best available randomized evidence says the money is probably better spent elsewhere.

Talk to your clinic about your specific numbers. Ask about their lab's mosaicism policy. And remember that the $4,000 you might spend on PGT-A could instead fund a second retrieval, an extra year of embryo storage, or a future FET.

Make an informed decision on your add-ons

Register at The Fertility Link to see clinics in your area that publish PGT-A outcomes by age band, and use our clinic matching tool to compare add-on pricing transparently. Your decision should be based on your numbers — not a generic clinic pitch.